Analyst Rating
based on 34 analysts
41.18%
Buy
32.35%
Hold
26.47%
Sell
Based on 34 analysts offering long term price targets for Lupin Ltd. An average target of ₹1982.26
Source: S&P Global Market Intelligence
Lupin Ltd Share analysis
Lupin Ltd price forecast by 34 analysts
Downside of
High
₹2515
Target
₹1982.26
Low
₹1284
Lupin Ltd target price ₹1982.26, a slight downside of -12.69% compared to current price of ₹2224.95. According to 34 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin Ltd revenue growth forecast
Expected growth rate Q1, FY2026:23.56%
Forecast
Actual
Including amortisation and stock based compensations
Lupin Ltd EPS growth forecast
EPS estimate Q1, FY2026:81.48%
Forecast
Actual
Source: S&P Global Market Intelligence
Performance
Day's Low
Day's High
₹2,213₹2,27952 Week's Low
52 Week's High
₹1,091.5₹2,312
| Returns % | |
| 1 Month Return | + 9.74 % |
| 3 Month Return | + 43.56 % |
| 1 Year Return | + 99.24 % |
| Market Stats | |
| Previous Close | ₹2,270.40 |
| Open | ₹2,274.00 |
| Volume | 5.04L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,03,561.44Cr |
Key Statistics
| P/E Ratio | 45.68 |
| PEG Ratio | 1.61 |
| Market Cap | ₹1,03,561.44 Cr |
| P/B Ratio | 3.58 |
| EPS | 42.47 |
| Dividend Yield | 0.49 |
| Sector | Pharmaceuticals |
| ROE | 11.92 |
Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹1,03,561.44 Cr | 39.82% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹16,557.65 Cr | 4.78% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹90,964.04 Cr | 30.18% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹1,11,787.57 Cr | 72.1% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹61,329.09 Cr | 38.09% | 0.53 | NA | NA |
Mutual Fund Holdings
Company Information
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Share Price: ₹2224.95 per share as on 18 Sep, 2024 04:01 PM
Market Capitalisation: ₹1,03,561.44Cr as of today
Revenue: ₹5,514.34Cr as on June 2024 (Q2 24)
Net Profit: ₹805.54Cr as on June 2024 (Q2 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Lupin Ltd
Lupin Partners with Takeda for Vonoprazan Launch - 18 Sep, 2024
Lupin Limited has signed a non-exclusive patent license agreement with Takeda to market Vonoprazan tablets in India, enhancing its gastroenterology portfolio. The drug will be available in 10 mg and 20 mg strengths, approved for various acid peptic disorders.
Lupin Faces Challenges Amid New Launches - 16 Sep, 2024
Nomura highlights Lupin as a buying opportunity among Indian drugmakers, citing upcoming launches like PredForte. However, the company faces market share declines in some drugs and recent litigation losses.
Lupin Partners with Sunsure Energy for Solar Power - 13 Sep, 2024
Sunsure Energy has signed an agreement to supply 21MW of solar power to Lupin's Tarapur facility, enhancing Lupin's commitment to renewable energy and sustainability.
Lupin Expands Renewable Energy Investments - 12 Sep, 2024
Lupin has partnered with Sunsure Energy to supply 21 MW solar power and signed an agreement to acquire a 43% stake in Sunsure Solarpark, enhancing its commitment to sustainability.
Lupin's Generic Jynarque Launch Faces Uncertainty - 09 Sep, 2024
Lupin's planned launch of generic Jynarque is now classified as 'at risk' due to Otsuka's appeal against a favorable court ruling, raising concerns about market share and earnings sustainability.
Lupin Ltd Reports Strong Growth and Market Position - 08 Sep, 2024
Lupin Limited's shares surged 70% year-to-date, reaching a 52-week high. The company reported a 16.3% revenue increase and a 78% rise in net profit in Q1 FY2025, driven by strong North American sales and a robust product pipeline.
Lupin Hits 52-Week High Amid FDA Approvals - 05 Sep, 2024
Lupin launched a generic version of Mirabegron tablets after FDA approval, leading to a 52-week high share price. However, the company also recalled Cefixime for being subpotent.
Lupin Launches Mirabegron Tablets Following FDA Approval - 04 Sep, 2024
On September 4, 2024, Lupin launched its generic Mirabegron extended-release tablets in the US after receiving USFDA approval, targeting a market worth $1.6 billion. Additionally, Lupin is recalling 4,554 bottles of Cefixime due to subpotency.
Lupin Shares Surge on Strong Earnings and New Launch - 30 Aug, 2024
Lupin Ltd's stock surged following a buy recommendation from Nomura, a successful drug launch in the US, and impressive earnings growth. The company anticipates continued growth in key markets, supported by strong US generics and a robust pipeline of new products.
Lupin Launches Generic Cancer Drug in US Market - 29 Aug, 2024
Lupin Ltd. has launched Doxorubicin Hydrochloride Liposome Injection in the US, a generic version of Doxil, indicated for treating ovarian cancer and multiple myeloma. The product follows FDA approval and has an estimated annual market of $40.9 million.
Lupin Secures FDA Approval for Ophthalmic Solution - 28 Aug, 2024
Lupin Limited announced FDA approval for its generic Brimonidine Tartrate Ophthalmic Solution, expected to tap into a market with annual sales of USD178.5 million.
Lupin Achieves Record Closing Amid Positive Sentiment - 27 Aug, 2024
Lupin Ltd has reached its highest-ever closing price, fueled by strong market positivity. The stock is expected to maintain a positive trend, with potential to reach Rs 2,240, while support is noted at Rs 2,059.
Health Canada Approves Lupin's Biosimilar Armlupeg - 24 Aug, 2024
Health Canada has approved Lupin's biosimilar Armlupeg (pegfilgrastim), manufactured in Pune, to help reduce infection risk after chemotherapy. This approval supports Canadian patients and enhances Lupin's presence in regulated markets.
Lupin Secures Approval for Cancer Treatment Biosimilar - 23 Aug, 2024
Lupin Limited has received approval from Health Canada for its biosimilar Pegfilgrastim, aimed at reducing infection risk in cancer patients undergoing chemotherapy. This approval strengthens Lupin's position in the biosimilars market.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 18.28% to 19.32% in Jun 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, LUPIN stock has moved up by 43.6%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 4.99K Cr → 5.66K Cr (in ₹), with an average increase of 12.0% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 359.43 Cr → 801.31 Cr (in ₹), with an average increase of 55.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 146.7% return, outperforming this stock by 3.5%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.93% to 6.92% in Jun 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 47.01% to 46.98% in Jun 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 16.82% to 16.23% in Jun 2024 quarter
Lupin Ltd Infographics
Lupin Ltd Q1 FY2024-2025 Results: Key Insights
Lupin reports 8th consecutive quarters of EBITDA improvement in Q1FY25
Company Financials
Index Inclusions
Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.98% | ||
| Foreign Institutions | 19.32% | 5.65 | |
| Mutual Funds | 16.23% | ||
| Retail Investors | 6.92% | ||
| Others | 10.55% |
Key Indicators
Lupin Ltd Valuation
Lupin Ltd in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (45.68x)
September 17, 2024
Industry (58.70x)
September 17, 2024
Highest (517.33x)
December 2, 2022
Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 77.18% since last year same period to ₹801.31Cr in the Q1 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 122.94% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.53%.
Read More about Dividends
Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bullish trading position according to technical analysis indicators.
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Lupin Ltd shares.
Lupin Ltd (LUPIN) share price today is ₹2224.95
Lupin Ltd is listed on NSE
Lupin Ltd is listed on BSE
- Today’s highest price of Lupin Ltd is ₹2279.
- Today’s lowest price of Lupin Ltd is ₹2213.
PE Ratio of Lupin Ltd is 45.68
PE ratio = Lupin Ltd Market price per share / Lupin Ltd Earnings per share
Today’s traded volume of Lupin Ltd(LUPIN) is 5.04L.
Today’s market capitalisation of Lupin Ltd(LUPIN) is ₹103561.44Cr.
| Lupin Ltd(LUPIN | Price |
|---|---|
52 Week High | ₹2312 |
52 Week Low | ₹1091.5 |
Lupin Ltd(LUPIN) share price is ₹2224.95. It is down -3.77% from its 52 Week High price of ₹2312
Lupin Ltd(LUPIN) share price is ₹2224.95. It is up 103.84% from its 52 Week Low price of ₹1091.5
| Lupin Ltd(LUPIN | Returns |
|---|---|
1 Day Returns | -45.45% |
1 Month Returns | 9.74% |
3 Month Returns | 43.56% |
1 Year Returns | 99.24% |